Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial.
Juming LuLiujun FuYan LiJianlin GengLi QinPing LiHailong ZhengZilin SunYan Bing LiLihui ZhangYadong SunDaoxiong ChenGui-Jun QinWeiping LuYushan GuoYuwei ZhangHaiyan LiuTao ZhangJianjun ZouPublished in: Diabetes, obesity & metabolism (2021)
Henagliflozin 5 mg and 10 mg as monotherapy provided effective glycaemic control, reduced body weight and blood pressure, and was generally well tolerated.